Daraxonrasib clinical trials
Also written RMC-6236.
Its developmentBy Revolution Medicines, step by step10 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.ClinicalTrials.gov finds 16 studies for daraxonrasib. How that becomes 14 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, to see whether and how it gives daraxonrasib. Its counts are asked again every night. How drug pages count
- 16Found by its intervention search · See all 16 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 14 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +6Give it under a name that search misses: a biosimilar’s code or a misspelling
- 22Give daraxonrasib to participants
- −1Observe patients on it, or give it outside a trial
- −7Give it beside what is tested
- 14Test it: the count on this site
Get an email when these change. Save the daraxonrasib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Aug 2026 · RASONQUE · NDA 220910 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (4); 3 more planned to start later
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 4
Revolution Medicines, Inc. (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · National Health Research Institutes, Taiwan (1) · Dana-Farber Cancer Institute (1) · Children's Oncology Group (1)
Often tested with
Tested in the same studies.
Zoldonrasib (3) · Gemcitabine (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Elironrasib (2) · Cetuximab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 4 most studied
New when their studies opened, with daraxonrasib beside them; studies of each.
- 1Navlimetostat
- 1PARP1 Inhibitor SNV1521
- 1KRAS G12V Inhibitor RMC-5127
- 1Zoldonrasib
Reaching primary completion within a year · 2
Studies that test daraxonrasib.
- May 2027Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASPhase 1/2 · Revolution Medicines, Inc.
- Jun 2027Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCPhase 1/2 · Revolution Medicines, Inc.
Studies
Open first, then newest update. How each study uses daraxonrasib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 14
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07491445Alone or with chemotherapy, against chemotherapy, first line in pancreatic cancerWritten as daraxonrasibHow we knowReport a problem
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07793253Alone in KRAS-mutant biliary tract cancerWritten as DaraxonrasibHow we knowReport a problem
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingPhase 3Revolution Medicines, Inc.NCT06881784Against docetaxel in RAS-mutant lung cancerWritten as daraxonrasibHow we knowReport a problem
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954With zoldonrasib, against chemotherapy, first line in G12D pancreatic cancerWritten as daraxonrasibHow we knowReport a problem
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338With ivonescimab, with or without chemotherapyWritten as DaraxonrasibHow we knowReport a problem
- Daraxonrasib in Asian RAS-mutant Biliary Tract CancerNot yet recruitingPhase 2National Health Research Institutes, TaiwanNCT07908550Alone in Asian patients with RAS-mutant biliary tract cancerWritten as DaraxonrasibHow we knowReport a problem
- Daraxonrasib in Resectable PDACNot yet recruitingPhase 1Dana-Farber Cancer InstituteNCT07898813Before and after surgery for resectable pancreatic cancerWritten as DaraxonrasibHow we knowReport a problem
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingPhase 3Revolution Medicines, Inc.NCT07252232Against observation after surgery for pancreatic cancerWritten as daraxonrasibHow we knowReport a problem
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221With pembrolizumab, chemotherapy or other RAS(ON) inhibitors in lung cancerWritten as RMC-6236How we knowReport a problem
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062With chemotherapy, bevacizumab or cetuximab in digestive cancersWritten as RMC-6236How we knowReport a problem
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06128551Alone and with elironrasib in KRAS G12C tumoursWritten as DaraxonrasibHow we knowReport a problem
- Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS MutationsNot yet recruitingPhase 1/2Children's Oncology GroupNCT07819838Alone in children with RAS-mutant solid tumoursWritten as DaraxonrasibHow we knowReport a problem
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingPhase 1/2Revolution Medicines, Inc.NCT05379985Alone in RAS-mutant solid tumours, first in peopleWritten as RMC-6236How we knowReport a problem
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingPhase 3Revolution Medicines, Inc.NCT06625320On the US labelAgainst chemotherapy in previously treated pancreatic cancerWritten as RMC-6236How we knowReport a problem
Behind its US label · 1 — the studies the FDA label of RASONQUE describes
From the Clinical Studies section of RASONQUE (2026-08), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 7 — no other medicine in its arm
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract CancerNot yet recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07793253Alone in KRAS-mutant biliary tract cancerWritten as DaraxonrasibHow we knowReport a problem
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingPhase 3Revolution Medicines, Inc.NCT06881784Against docetaxel in RAS-mutant lung cancerWritten as daraxonrasibHow we knowReport a problem
- Daraxonrasib in Asian RAS-mutant Biliary Tract CancerNot yet recruitingPhase 2National Health Research Institutes, TaiwanNCT07908550Alone in Asian patients with RAS-mutant biliary tract cancerWritten as DaraxonrasibHow we knowReport a problem
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingPhase 3Revolution Medicines, Inc.NCT07252232Against observation after surgery for pancreatic cancerWritten as daraxonrasibHow we knowReport a problem
- Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS MutationsNot yet recruitingPhase 1/2Children's Oncology GroupNCT07819838Alone in children with RAS-mutant solid tumoursWritten as DaraxonrasibHow we knowReport a problem
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingPhase 1/2Revolution Medicines, Inc.NCT05379985Alone in RAS-mutant solid tumours, first in peopleWritten as RMC-6236How we knowReport a problem
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingPhase 3Revolution Medicines, Inc.NCT06625320On the US labelAgainst chemotherapy in previously treated pancreatic cancerWritten as RMC-6236How we knowReport a problem
Tested with established drugs · 2 — they are given beside it
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT07397338With ivonescimab, with or without chemotherapyWritten as DaraxonrasibHow we knowReport a problem
- Daraxonrasib in Resectable PDACNot yet recruitingPhase 1Dana-Farber Cancer InstituteNCT07898813Before and after surgery for resectable pancreatic cancerWritten as DaraxonrasibHow we knowReport a problem
Tested in a combination · 5 — another drug in the study is under test too
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07491445Alone or with chemotherapy, against chemotherapy, first line in pancreatic cancerWritten as daraxonrasibHow we knowReport a problem
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954With zoldonrasib, against chemotherapy, first line in G12D pancreatic cancerWritten as daraxonrasibHow we knowReport a problem
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221With pembrolizumab, chemotherapy or other RAS(ON) inhibitors in lung cancerWritten as RMC-6236How we knowReport a problem
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06445062With chemotherapy, bevacizumab or cetuximab in digestive cancersWritten as RMC-6236How we knowReport a problem
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingPhase 1/2Revolution Medicines, Inc.NCT06128551Alone and with elironrasib in KRAS G12C tumoursWritten as DaraxonrasibHow we knowReport a problem
Beside a new treatment under test · 6 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with daraxonrasib: navlimetostat 1 · PARP1 Inhibitor SNV1521 1 · KRAS G12V Inhibitor RMC-5127 1 · zoldonrasib 1
- A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)RecruitingPhase 2Bristol-Myers SquibbNCT07492680Given with navlimetostat in some cohortsWritten as DaraxonrasibHow we knowReport a problem
- First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerRecruitingPhase 1ParVation Therapeutics, Inc.NCT07756281In every armGiven with SNV1521, the drug being dosedWritten as daraxonrasibHow we knowReport a problem
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06922591Given with TNG462, the drug being dosedWritten as RMC-6236How we knowReport a problem
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT07349537Given with RMC-5127 in one armWritten as daraxonrasibHow we knowReport a problem
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingPhase 1Revolution Medicines, Inc.NCT06040541Given with zoldonrasib in its combination armWritten as RMC-6236How we knowReport a problem
- A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)Active, not recruitingPhase 1AmgenNCT06360354Given with anvumetostat in one pancreatic cancer subprotocolWritten as RMC-6236How we knowReport a problem
Beside supportive care · 1 — a supportive treatment or test is studied
Observed · 1 — patients on it are followed, or it is given outside a trial
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered2
- Daraxonrasib in Asian RAS-mutant Biliary Tract CancerNov 2, 2026NCT07908550
- Daraxonrasib in Resectable PDACOct 27, 2026NCT07898813
Codes
What other systems call daraxonrasib · ClinicalTrials.gg INT002100
- MeSH (NLM) C000731071daraxonrasibOne source NLM
- UNII (FDA) B6T47Y2UAPDARAXONRASIBConfirmed FDA, NLM, Wikidata
- Wikidata Q136659312daraxonrasibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C188048DaraxonrasibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731071 | daraxonrasib | One source NLM |
| UNII (FDA) | B6T47Y2UAP | DARAXONRASIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q136659312 | daraxonrasib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C188048 | Daraxonrasib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.